Hyundai developing ‘transformer-class’ walking car

So-called “flying cars” may be all the buzz these days, but Hyundai has established a new team in Silicon Valley tasked with developing a production version of the futuristic Elevate walking vehicle concept it unveiled at CES in 2019.

The vehicle is equipped with robotic legs that have wheels instead of feet that allow it to drive like a car and also lift the body off the ground to traverse rough terrain in a walking motion.

“We aim to create the world’s first transformer-class vehicle, also known as the Ultimate Mobility Vehicle,” said vice president Dr. John Suh, who is director of the New Horizons Studio.

ALSO READ: PLATEAU KILLINGS: Provide security for the people, senate to security agencies

Hyundai thinks there is a wide variety of use cases for such a vehicle, including emergency first response in hard to reach areas and providing wheelchair access to buildings without ramp-equipped entrances.

Hyundai did not say when it expects to have a working prototype or production vehicle ready.

Of course, like many automakers, Hyundai’s feet may be on the ground but it is reaching for the sky. At the 2020 edition of CES, it announced a project to develop an air taxi in partnership with Uber called the S-A1.

NY Post

Vanguard

The post Hyundai developing ‘transformer-class’ walking car appeared first on Vanguard News.

by Temisan Amoye via Vanguard News https://ift.tt/3cKOnIg Best Known Member of the Cabinet Wikipedia

Comments

Effective Data Governance: IIM-Africa inks partnership deal with Data Management University

President/Chairman of the governing council of IIM-Africa, Dr. Oyedokun Oyewole has said that effective data governance strategy has become more essential for the survival and sustenance of government and businesses, especially with the sudden outbreak of COVID-19 Pandemic. Oyewole said there is the need to ensure that the right policies, processes, technology, and people are in place to effectively manage data while complying with legal and regulatory requirements. He said that as part of the IIM Africa’s commitments towards ensuring global best practices, it has entered into a long-term partnership with DataManagementU.com to bring the finest data management training to industries across Africa. READ ALSO: COVID-19: Foreign affairs minister says first set of Nigerians abroad to be evacuated soon According to the IIM President, the alliance is expected to provide members of the Institute and other professionals across Africa, high standards, internationally-recognized learn...

Naomi Osaka’s statement about withdrawing from French Open

Japan’s Naomi Osaka returns the ball to Romania’s Patricia Maria Tig during their first round match of the French open tennis tournament at the Roland Garros stadium Sunday, May 30, 2021 in Paris. (AP Photo/Christophe Ena) Naomi Osaka tweeted the following statement announcing her withdrawal from the French Open on Monday: “Hey everyone, this isn’t a situation I ever imagined or intended when I posted a few days ago. I think now the best thing for the tournament, the other players and my well-being is that I withdraw so that everyone can get back to focusing on the tennis going on in Paris. ”I never wanted to be a distraction and I accept that my timing was not idea and my message could have been clearer. ”More importantly I would never trivialize mental health or use the term lightly. The truth is that I have suffered long bouts of depression since the US Open in 2018 and I have had a really hard time coping with that. Anyone that knows me knows I’m introverted, and anyone tha...

Remdesivir: The COVID-19 drug helping patients recover faster

A vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States. PHOTO: AP Remdesivir has been shown to speed up recovery times for patients with COVID-19 in a major US-led trial, becoming the first drug with proven benefit against the disease. Here is what you need to know. – What is remdesivir? – Remdesivir is an experimental, broad spectrum antiviral made by US pharmaceutical Gilead Sciences that was first developed to treat Ebola, a viral hemorrhagic fever. It showed early promise in a primate study in 2016 and was later rolled out for a major trial in the Democratic Republic of Congo, where it was compared against three other medicines. That study concluded in 2019 when it was discontinued because it did not boost survival rates as greatly as two monoclonal antibody drugs, which are lab-engineered immune system proteins. In February, the US National Institute of Allergy and Infectious Diseases (NIAID) announced ...

Thorian

Search This Blog